Penumbra (PEN) Cash from Investing Activities (2014 - 2026)
Penumbra (PEN) reported Cash from Investing Activities of -$30.6 million for Q1 2026, down 6002.19% year-over-year from $519010.6 in Q1 2025, and up 86.42% quarter-over-quarter from -$225.6 million in Q4 2025.
Penumbra (PEN) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Cash from Investing Activities data on file, last reported at -$30.6 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$30.6 million, down 6002.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$434.7 million (down 840.1% YoY), and the FY2025 annual result was -$404.6 million, down 621.22% from the prior year.
- Cash from Investing Activities climbed to -$30.6 million in Q1 2026 per PEN's latest filing, from -$225.6 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $35.7 million in Q3 2024 and troughed at -$225.6 million in Q4 2025.
- A 5-year average of -$18.8 million and a median of $8.6 million in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities surged 744.73% in 2022, then tumbled 6002.19% in 2026.
- A 5-year view of Cash from Investing Activities shows it stood at $8.6 million in 2022, then soared by 181.25% to $24.3 million in 2023, then slumped by 145.12% to -$11.0 million in 2024, then sank by 1959.76% to -$225.6 million in 2025, then surged by 86.42% to -$30.6 million in 2026.
- Business Quant data shows PEN's Cash from Investing Activities at -$30.6 million in Q1 2026, -$225.6 million in Q4 2025, and -$162.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -816.00 Mn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -92.80 Mn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -2.50 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -475.32 Mn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | -298.50 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | -217.20 Mn |
| 10 | Penumbra | 12.51 Bn | 11.90 Bn | 253.41 Mn | -30.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.63 Mn |
| Mar 31, 2026 | -30.63 Mn |
| Dec 31, 2025 | -225.65 Mn |
| Dec 31, 2025 | -225.65 Mn |
| Sep 30, 2025 | -162.86 Mn |
| Sep 30, 2025 | -162.86 Mn |
| Jun 30, 2025 | -15.58 Mn |
| Jun 30, 2025 | -15.58 Mn |
| Mar 31, 2025 | -502,000.00 |
| Mar 31, 2025 | -502,000.00 |
| Dec 31, 2024 | -10.96 Mn |
| Dec 31, 2024 | -10.96 Mn |
| Sep 30, 2024 | 35.72 Mn |
| Sep 30, 2024 | 35.72 Mn |
| Jun 30, 2024 | 34.47 Mn |
| Jun 30, 2024 | 34.47 Mn |
| Mar 31, 2024 | 18.38 Mn |
| Mar 31, 2024 | 18.38 Mn |
| Dec 31, 2023 | 24.28 Mn |
| Dec 31, 2023 | 24.28 Mn |